Core Viewpoint - Lantheus (NASDAQ: LNTH) has seen a significant stock decline of 50% over the past year due to poor financial results, lowered guidance, and increased competition, which is viewed as a justified decline [1]. Company Performance - The company reported disappointing results that contributed to the stock's decline [1]. - Guidance for future performance has been reduced, indicating potential ongoing challenges [1]. Competitive Environment - The competitive landscape has become tougher for Lantheus, which may impact its market position and profitability [1].

Lantheus (NASDAQ: LNTH ) has experienced a 50% stock drop in the last year, amid poor reported results, reduced guidance and a clearly tougher competitive environment. I think the decline is justified and it's not an easyMy name is María Fernanda and I'm currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, so I look to predi ...

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-form-2/?id=171663&from=3 CLASS PERIO ...

RADNOR, Pa., Oct. 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Lan ...

Core Insights - Lantheus Holdings Inc. is currently viewed as a value stock, but has faced a downgrade from Goldman Sachs due to pricing pressures and slower uptake of Alzheimer's therapeutics [1][3] - The company reported Q2 2025 sales of $378.05 million, reflecting a year-over-year decline of 4.07% [2] - An exclusive licensing agreement was established with GE HealthCare for the prostate cancer imaging agent PYLARIFY, which will be developed and commercialized in Japan [2][3] - Lantheus's MK-6240 radiodiagnostic has shown promising results in pivotal studies for Alzheimer's disease, confirming its diagnostic capabilities [3][4] Financial Performance - Q2 2025 sales amounted to $378.05 million, marking a 4.07% decrease compared to the previous year [2] - The downgrade from Goldman Sachs included a price target reduction from $110 to $77 [1] Strategic Developments - Lantheus entered into an exclusive licensing agreement with GE HealthCare for PYLARIFY, aimed at enhancing prostate cancer diagnostics in Japan [2] - The company has made advancements in Alzheimer's diagnostics with MK-6240, which met its co-primary endpoints in clinical studies [3]

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LNTH during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 10, 2025. There is no cost or obligation to you to participate in this cas ...

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Lantheus class action lawsuit – captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities and charges Lantheus as well as certain of Lantheus's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Lantheus class action l ...

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product Pylarify and its competitive position during the specified Class Period [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately prepared to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 10, 2025 [7].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The complaint claims that Lantheus misled investors about PYLARIFY's competitive position and failed to adequately assess pricing dynamics, which could jeopardize the product's revenue and growth potential [2]. - It is alleged that Lantheus did not disclose the implications of a price increase in early 2025, which followed a year of price erosion, potentially allowing for competitive pricing to undermine PYLARIFY's market position [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to apply to be appointed as lead plaintiffs, representing the class in the lawsuit [3]. - The lead plaintiff will select legal counsel to represent the class, and participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...